Amnion Chorion Cell Detection for Preterm Birth Risk
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for predicting pre-term birth in pregnant women are not robust enough, lacking effective markers to identify those at increased risk, which hinders timely intervention and management of associated complications.
Innovation Solution
The method involves detecting specific amnion and chorion cells in a blood sample using markers such as IGF2, IGFB3, SERPINB10, and others, indicating pre-term birth or increased risk, allowing for early identification and treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current prediction methods are used, then existing diagnostic capabilities are maintained, but the ability to robustly identify pregnant women at increased risk of pre-term birth is insufficient
Solution Approach 1:
The invention segments the diagnostic approach by identifying and measuring specific fetal membrane cells (amnion and chorion cells) as distinct markers in maternal blood. This segmentation allows for more precise identification of pre-term birth risk compared to general prediction methods, directly improving measurement precision while enhancing prediction reliability through targeted cell detection
Solution Approach 2:
The invention introduces fetal membrane cells as intermediary markers that mediate between the underlying biological processes of pre-term birth and the diagnostic measurement. These cells serve as measurable intermediaries that provide robust identification capability, resolving the contradiction by enabling precise measurement through a reliable intermediate target
2Loss of time
If early detection methods are implemented, then timely intervention is enabled, but the complexity of detecting specific amnion and chorion cells increases
Solution Approach 1:
The invention applies universal detection methods (flow cytometry, immunocytochemistry) that can identify multiple fetal membrane cell types using common markers. This multi-functionality enables early detection of various cell types with a single standardized protocol, reducing the practical complexity despite the sophisticated nature of early detection requirements
Solution Approach 2:
The invention changes the detection parameter from general biomarkers to specific cell surface markers on fetal membrane cells. This parameter change enables early detection through standardized immunological methods, balancing the need for timely intervention with manageable detection complexity using well-established laboratory techniques
Data Source
AI summary
The present invention includes a method for determining pre-term birth or an associated clinical condition or an increased risk of pre-term birth or an associated clinical condition based on the presence and/or increased amount of specific amnion and/or chorion cells in a blood sample from a pregnant woman.